The Amyloidosis Channel is supported with funding from Prothena (Silver).
The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ISA 2024 | Considerations for the timing of transplantation in AL amyloidosis
Maximilian Steinhardt, MD, University Hospital Würzburg, Würzburg, Germany, discusses important factors to consider when selecting and timing patients with light chain (AL) amyloidosis for stem cell transplantation (SCT). Once a patient is eligible for SCT and agrees to it, this is usually done as quickly as possible on the basis that a deep remission is needed. Further research is required to establish whether late transplantation loses efficacy and plays a role in relapse. This interview took place at the XIX International Symposium on Amyloidosis (ISA) in Rochester, MN.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Travel funds from Janssen
